U.S. government to test Pfizer’s Paxlovid for long COVID

(Reuters) The U.S. National Institutes of Health’s $1 billion RECOVER Initiative has picked Pfizer Inc’s (PFE.N) antiviral drug Paxlovid as the first treatment it will study in patients with long COVID, organizers of the study said on Thursday. The complex medical condition involves more than 200 symptoms ranging from exhaustion and cognitive impairment to pain, fever and heart palpitations that can last for months and even years following a COVID-19 infection.